Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

$24.99

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Amgen Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Accounts payable
Accrued liabilities
Current portion of long-term debt
Current liabilities
Long-term debt, excluding current portion
Long-term deferred tax liabilities
Long-term tax liabilities
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Common stock and additional paid-in capital; $0.0001 par value
Accumulated deficit
Accumulated other comprehensive loss
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The liabilities and stockholders’ equity of the company exhibit notable fluctuations over the observed period from March 2021 to December 2025. Overall, total liabilities generally increased, with a significant jump in late 2022 and early 2023, before stabilizing and decreasing slightly towards the end of the period. Stockholders’ equity experienced a more volatile trajectory, initially declining before a substantial recovery and subsequent moderate fluctuations.

Current Liabilities
Current liabilities demonstrated an initial increase from $12.869 billion in March 2021 to a peak of $15.687 billion in December 2022. This was followed by a decrease to $15.687 billion in December 2022, then a rise to $25.489 billion in December 2025. A significant driver of this trend appears to be the accounts payable, which increased substantially from $1.396 billion in March 2021 to $3.010 billion in June 2025, before decreasing to $2.367 billion in December 2025. Accrued liabilities also consistently increased over the period, rising from $9.917 billion to $18.523 billion. The current portion of long-term debt showed considerable volatility, peaking at $4.324 billion in June 2021, then decreasing significantly before rising again to $4.599 billion in December 2025.
Noncurrent Liabilities
Noncurrent liabilities generally increased from $40.336 billion in March 2021 to $45.773 billion in December 2022, then experienced a substantial increase to $83.372 billion in March 2023. This was largely driven by a significant increase in long-term debt, excluding the current portion, which rose from $31.129 billion in March 2021 to $60.761 billion in March 2023. Subsequently, noncurrent liabilities decreased to $56.439 billion in December 2025, with long-term debt decreasing to $50.005 billion. Long-term tax liabilities decreased steadily over the period, from $7.037 billion to $2.690 billion. Long-term deferred tax liabilities were first reported in September 2022 and decreased from $2.354 billion to $1.366 billion in December 2025. Other noncurrent liabilities remained relatively stable, fluctuating between $2.170 billion and $2.949 billion.
Stockholders’ Equity
Stockholders’ equity experienced a decline from $9.334 billion in March 2021 to a low of $6.700 billion in June 2022. A substantial recovery followed, with equity increasing to $9.619 billion in September 2025. This recovery was primarily driven by an increase in common stock and additional paid-in capital, which remained relatively stable around $32-34 billion, and a reduction in accumulated deficit, which decreased from -$24.600 billion in June 2022 to -$25.107 billion in December 2025. Accumulated other comprehensive loss also decreased over the period, from -$833 million to -$258 million.

In summary, the company’s balance sheet reflects a trend of increasing liabilities, particularly in the short term, alongside a recovery in stockholders’ equity. The significant increase in long-term debt in early 2023 warrants further investigation, as does the substantial rise in accounts payable and accrued liabilities. The reduction in accumulated deficit contributed positively to the improvement in stockholders’ equity.